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Abstract
We have identified human ArhGAP9 as a novel MAP kinase docking protein that interacts with
Erk2 and p38α through complementarily charged residues in the WW domain of ArhGAP9 and
the CD domains of Erk2 and p38α. This interaction sequesters the MAP kinases in their inactive
states through displacement of MAP kinase kinases targeting the same sites. While over-expression
of wild type ArhGAP9 caused MAP kinase activation by the epidermal growth factor receptor
(EGFR) to be suppressed and preserved the actin stress fibres in quiescent Swiss 3T3 fibroblasts,
over-expression of an ArhGAP9 mutant defective in MAP kinase binding restored EGFR-induced
MAP kinase activation and resulted in significant disruption of the stress fibres, consistent with the
role of Erk activation in disassembly of actin stress fibres. The interaction between ArhGAP9 and
the MAP kinases represents a novel mechanism of cross-talk between Rho GTPase and MAP kinase
signaling.
Background
The extensive study of the molecular mechanisms of intra-
cellular signal transduction over the past two decades
have elucidated major pathways that are important in
controlling cell functions and have provided important
insights in drug discovery. Two of the most well-studied
pathways include the Mitogen-activated protein (MAP)
kinase cascade and signaling by small-GTP binding
GTPases of the Ras superfamily. These pathways are essen-
tial in normal development and aberrant functions have
resulted in a wide range of pathophysiological conditions.
The MAP kinase cascades play important roles in a wide
variety of cellular functions and are evolutionarily con-
served. In mammals there are four subfamily members,
namely, Erk1/2, p38, Jnk and Erk5. Each MAP kinase has
its own activators, substrates and inactivators. The MAP
kinase cascade is tightly regulated in order to achieve cel-
lular functions that are spatially and temporally precise.
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Recent studies have revealed two mechanisms regulating
the MAP kinase signaling, namely the docking and scaf-
folding interactions. MAP kinases possess a common
docking (CD) domain that is localized to the C-terminal
region of the kinase domain for interaction with docking
proteins including upstream activating kinases MAP
kinase kinases (MAPKKs), MAP kinases activating protein
kinases (MAPKAPs), MAP kinase-specific phosphatases
(MKPs) and MAP kinase substrates such as Elk [1]. These
docking proteins all contain basic residues in the Docking
(D) domain that form electrostatic interactions with
acidic residues in the CD domain of the MAP kinases [1].
Scaffolding proteins interact with several components of
the MAP kinase cascades to assemble the enzymes and
substrates into a same complex to achieve signaling specif-
icity [2].
The Rho GTPases are principally involved in the regula-
tion of the actin cytoskeleton. The switch mechanism of
Rho GTPases is tightly regulated through binding to GTP
or GDP [1,2]. The human genome contains 22 Rho
GTPases, 80 Rho Guanine nucleotide Exchange Factors
(RhoGEF's) which catalyze the GDP exchange by GTP and
about same number of Rho GTPase-Activating Proteins
(RhoGAP's) which bind to Rho proteins to increase their
rates of hydrolysis of bound GTP. The RhoGAP's serve as
important negative regulators of Rho signaling [3-5].
The abundance of Rho proteins and their regulators and
the discovery of mutations in a number of them in human
diseases underscore the importance of Rho GTPase signal-
ing in normal and aberrant development [6,7]. For exam-
ple, studies in p190 RhoGAP knockout mice showed that
the RhoGAP is required for axon outgrowth, guidance and
fasciculation and neuronal morphogenesis [8,9]. Genetic
aberrations in two neuronal RhoGAPs, namely oligo-
phrenin and MeGAP/srGAP3, had been found in two dis-
tinct types of human mental retardation [10,11].
Defective Rho GTPase signaling has also been implicated
in tumorigenesis and metastasis [7,12]. The RhoGAP
member  DLC1  (Deleted in Liver Cancer 1) had been
shown to be deleted in a large number of primary hepato-
cellular carcinoma (HCC) and HCC cell with the implica-
tion of its role in the inhibition of tumorigenicity and
invasiveness [13,14]. The focal adhesion kinase associated
RhoGAP, GRAF, was identified as a fusion partner of the
mixed-lineage leukemia (MLL) gene by unique chromo-
some translocation in juvenile myelomonocytic leukemia
[15]. The fusion of BCR with ABL oncogene is a leukemia-
associated chromosomal translocation which resulted in
the fusion proteins p120 and p190 that lacked the
RhoGAP domain of BCR [16].
The RhoGAP family is defined by the presence of a ~150
amino acid conserved RhoGAP domain in the primary
sequences of proteins and shares at least 20% sequence
homology amongst the family members [3,16]. The bind-
ing of the RhoGAP domain with GTP-bound Rho proteins
accelerates the GTPase activity of the latter. One subfamily
of recently discovered RhoGAP proteins consisting of
ArhGAP9 and ArhGAP12 contain a diverse combination
of functional protein domains, including RhoGAP, SH3,
WW and PH domains [17,18]. ArhGAP9 was reported to
be active towards cdc42 and Rac1 but not RhoA and to
repress the adhesion of a human leukemia cell line KG-1
to fibronectin and collagen [17].
One major theme important in molecular signaling is reg-
ulated protein-protein interactions which result in the
assembly of protein complexes to transmit intracellular
signals, allow for control of signaling specificity and
mediate cross-talk between different pathways to coordi-
nate signaling outcomes. These regulated molecular inter-
actions occur through defined protein domains and
complementary recognition motifs on the binding part-
ners.
The WW domain is a 35–40 amino acid protein interac-
tion domain with two signature tryptophan residues
spaced by 22 amino acids [19,20]. WW domains recog-
nize several classes of distinct peptide ligands comprising
proline-rich sequences, such as PPDY, PPLP, PPPPP, PPX-
PPXR, PPRXXP (X: any amino acid), PR motifs or phos-
phorylated threonine or serine-proline (pT/pS)-P sites.
WW domains are found in many eukaryotes and are
present in approximately 50 human proteins [19] and
have been classified into four groups based on their bind-
ing to the different types of peptide ligands. Group I WW
domains have been shown to recognize PY motifs, Groups
II and III WW domains have relatively broad and overlap-
ping specificity for ligands comprising PPLP and PR
motifs, and Group IV WW domains recognize (pS/pT)-P
motifs. Disruption of WW domain interactions has been
implicated in cancer [21-23] and in hereditary disorders
such as Duchenne muscular dystrophy [20], the Liddle
syndrome of hypertension [24,25], the Rett syndrome
[26], as well as in Alzheimer's [27-29] and Huntington's
diseases [30,31].
We report here that human ArhGAP9 is a novel docking
protein of the MAP kinases Erk2 and p38α. We show that
the binding sites involved clusters of complementarily
charges residues located in the common docking (CD)
domain of Erk and p38 and the C-terminal region of the
WW domain of ArhGAP9, and that through this interac-
tion, cross-talk between the Rho GTPase and MAP kinase
signaling pathways could occur to control actin remode-
ling.Journal of Molecular Signaling 2007, 2:1 http://www.jmolecularsignaling.com/content/2/1/1
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Results
Novel interaction between Erk and p38 MAP kinases and 
the WW domain of the ArhGAP9 RhoGAP
ArhGAP9 and ArhGAP12 are highly similar RhoGAP pro-
teins which possess the SH3, WW, PH and RhoGAP
domains. We have cloned the full-length mouse ArhGAP9
cDNA (GeneBank accession no. DQ498128) and found
that although it shares 64% sequence identity with
human ArhGAP9, it lacks the WW domain (Fig. 1a).
According to the SMART domain prediction tool [32],
bovine, canine and primate ArhGAP9 contain the SH3,
WW, PH and RhoGAP domains, murine and rat ArhGAP9
contain the SH3, PH and RhoGAP domains and lack the
WW domain. It is possible that genomic deletion resulting
in the loss of the WW domain in ArhGAP9 has occurred
rodents. To understand the signaling function of the WW
domain in ArhGAP9 of organisms that retain this domain,
we screened for interacting proteins for the WW domain
of human ArhGAP9. The GST fusion protein of the WW
domain of human ArhGAP9 immobilized on glutathione
Sepharose beads was used as a bait to isolate interacting
proteins from rat brain lysate using proteomics (Fig. 1b).
Several specific binding proteins were identified, includ-
ing the MAP kinase Erk2 from bands f and g that gener-
ated 15 unique peptides covering 40% of the protein
sequence of Mitogen-activated protein kinase 1 (MAPK1,
also Erk2). The other bands corresponded to other pro-
teins were characterized separately from this report.
Binding of Erk2 and p38α to human ArhGAP9 in vitro and 
in vivo
Erk2 binding to the WW domain of human ArhGAP9 was
confirmed by in vitro pulldown assays (Fig. 2a). Flag-
tagged Erk2 was expressed in 293T cells and the lysates
prepared were incubated with GST fusion protein of the
WW domain of ArhGAP9 immobilized on glutathione
Sepharose beads (ArhGAP9-WW-GST). The binding of
two closely related MAP kinases, p38α and Jnk1, was also
tested. Consistent with the proteomics data, Erk2 was pre-
cipitated by ArhGAP9-WW-GST [Fig. 2a(i)]. While p38α
also showed binding albeit to a lesser extent than Erk2,
the binding of Jnk1 was not detectable in the pulldown
assay. Full-length ArhGAP9 was also shown to be able to
bind to immobilized recombinant Erk2 or p38α (Fig. 2b).
Using coimmunoprecipitation experiments, the binding
of Erk2 or p38α to ArhGAP9 in vivo was confirmed [Fig.
2c(i)]. Given that Erk2 and p38α showed no binding to
the two WW domains of ArhGAP12 (ArhGAP12-WW1
and ArhGAP12-WW2) or the first WW domain of Nedd4
(Nedd4-WW1) [Fig. 2d(i)], the binding of Erk2 and p38α
to the WW domain of ArhGAP9 was specific.
As mouse ArhGAP9 does not contain a WW domain, we
tested whether the protein would be able to interact with
the MAP kinases Erk2 and p38α like the human ortholog.
A GST fusion of an N-terminal fragment of the mouse
ArhGAP9 protein (mArhGAP9-N), comprising of amino
acids 1–350 which included the SH3 and PH domain and
the intervening sequence between these two domains was
found to be unable to bind to Erk2 and p38α, when com-
pared to human ArhGAP9 WW domain [Fig. 2e(ii)].
Using coimmunoprecipitation experiments, it was con-
firmed that full-length mouse ArhGAP9 could not interact
with Erk2 in vivo (Fig. 2f). Taken together, we conclude
that human ArhGAP9 interacted with Erk2 and p38α spe-
cifically with its WW domain and the mouse ortholog
which lacked a WW domain was unable to bind to MAP
kinases.
MAP kinase and ArhGAP9 binding was mediated by 
complementarily charged residues in CD and WW 
domains, respectively
Sequence alignment of human ArhGAP9-WW domain
with all the known WW domains showed that the C-ter-
minal end of human ArhGAP9-WW domain contained a
unique basic di-Arginine motif (R246 and R247) that are
not present in all other WW domains compared (data not
shown). The alignment of the WW domains of human
ArhGAP12 and ArhGAP9 showed that in the first and sec-
ond WW domains of ArhGAP12 which did not bind Erk2
and p38α, the amino acids in alignment with R247 are
hydrophobic residues W and Y, respectively (Fig. 3a).
Such short basic motifs, termed Docking (D) domains,
had been found to be present in many MAP kinase dock-
ing proteins that bind to the conserved docking (CD)
domains of MAP kinases [33-36]. The CD domains of
Erk2, p38 and Jnk consist of conserved acidic residues
which form electrostatic interactions with the basic resi-
dues of the target docking proteins [33-36]. Therefore we
examined the possibility that the interaction between the
complementarily charged residues in the CD domains of
Erk2 or p38α and WW domain of ArhGAP9 could be the
mechanism which enhanced or mediated the binding of
these MAP kinases and ArhGAP9. We investigated
whether the basic residues in the WW domain of human
ArhGAP9 would mediate the binding to Erk2 and p38α
through interaction with the acidic residues in the CD
domain, as in the case of other MAP kinase docking pro-
teins. R246 and R247 in the WW domain of human
ArhGAP9 were mutated to Alanine (ArhGAP9-WW-RR)
and the binding of Erk2, p38α or Jnk1 was tested. As
shown in Fig. 3b(i), for both Erk2 and p38α, the binding
to the WW domain with R246, 247A mutation was signif-
icantly reduced compared to binding to wild type
ArhGAP9 WW domain, confirming that these basic resi-
dues played a role in MAP kinase interaction. Single muta-
tion of R246A or R247A was also defective in binding to
Erk2 (Fig. 3c). The binding of full-length R246, 247A (RR)
mutant of ArhGAP9 to Erk2 or p38α was significantly
reduced relative to wild type ArhGAP9 in vivo using coim-Journal of Molecular Signaling 2007, 2:1 http://www.jmolecularsignaling.com/content/2/1/1
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munoprecipitation experiments (Fig. 3d). Therefore,
R246 and R247 in the WW domain of ArhGAP9 are
important in mediating the binding to Erk and p38 MAP
kinases. Further binding analysis indicated that residues
in the vicinity of this di-Arginine motif, namely, K243,
P244 and P245 with the WW domain also contributed to
binding of ArhGAP9 with MAP kinases (Fig. 3e).
To examine whether the CD domains in the MAP kinases
Erk2 and p38α were the regions that interacted with the
WW domain of ArhGAP9, GST fusions of a C-terminal
fragment of Erk2 containing the CD domain (Erk2-CD-
GST, residues 300–358) and a deleted version of Erk2
lacking the CD domain (Erk2-∆CD-GST, residues 1–300)
were constructed. The binding of wild type or R246, 247A
mutant of ArhGAP9 with immobilized Erk2-CD-GST and
Erk2-∆CD-GST were tested [Fig. 4a(i)]. Wild type
ArhGAP9 but not the R246, 247A mutant, specifically pre-
cipitated with Erk2-CD-GST, indicating that the CD
domain was sufficient to mediate Erk2 binding to
ArhGAP9. Consistent with this notion, Erk2-∆CD-GST
did not bind wild type ArhGAP9 [Fig. 4a(ii)].
To further determine whether the conserved acidic resi-
dues [Fig. 4b(i)] in the CD domains of the MAP kinases
were important in mediating binding to the WW domain
Erk2 binds to human ArhGAP9 at the WW domain Figure 1
Erk2 binds to human ArhGAP9 at the WW domain. a. Evolutionary conservation of ArhGAP9 and ArhGAP12. Schematic repre-
sentation of ArhGAP9 and ArhGAP12 domain structures of different species as predicted by SMART domain prediction tool. 
b. Identification of Erk2 as an interacting protein of the WW domain of human ArhGAP9. Immobilized ArhGAP9-WW-GST precipi-
tated several proteins (bands a-g) from rat brain lysate detected by Colloidal Coomassie Blue. The bands were excised for in-
gel reduction, S-alkylation and trypsin hydrolysis. The peptides were identified by mass spectrometry. Bands f and g generated 
15 unique peptides covering 40% of the MAP kinase, Erk2 sequence.
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Erk2 and p38α, but not Jnk1 interacted with ArhGAP9 WW domain Figure 2
Erk2 and p38α, but not Jnk1 interacted with ArhGAP9 WW domain. a. Specificity of Erk2 and p38α binding to the WW 
domain of ArhGAP9. MAP kinases, Erk2-Flag, p38α-Flag or Jnk1-Flag, were transiently expressed in 293T cells and the lysates 
used for in vitro binding assay with (i) ArhGAP9-WW-GST or (ii) GST control, followed by western blotting with α-Flag. (iii) 
Total cell lysates were separated by SDS-PAGE and immunoblotted with α-Flag. b. Full length Erk2 and p38α interact with 
ArhGAP9 in vitro. Flag-tagged ArhGAP9 was expressed in 293T cells and the lysates were incubated with immobilized (i) Erk2-
GST, (ii) p38α-GST or (iii) GST alone as a control. Bound Erk2 and p38α was detected by western blotting with α-Flag. (iv) 
Total lysates were immunoblotted with α-Flag. c. Interaction of ArhGAP9 with MAP kinases in vivo. ArhGAP9 and MAP kinases, 
Erk2-Flag or p38α-Flag were expressed in 293T cells. The lysates were immunoprecipitated with α-Flag, followed by western 
blotting with (i) α-ArhGAP9 or (ii) α-Flag. (iii, iv) Immunoblotting of total cell lysates with α-ArhGAP9 or α-Flag. d. Erk2 and 
p38α interact specifically with the WW domain of ArhGAP9 but not ArhGAP12 or Nedd4. MAP kinases Erk2-Flag, p38α-Flag or Jnk1-
Flag was expressed in 293T cells and the lysates were incubated with GST fusion proteins of the WW domains of ArhGAP9, 
ArhGAP12 or Nedd4, or GST alone immobilized on glutathione Sepharose beads, as indicated in the figure. (i) Specifically 
bound proteins were detected by western blotting with α-Flag. (ii) Total cell lysates were immunoblotted with α-Flag. e. Erk2 
and p38α do not interact with mouse ArhGAP9 in vitro. Flag-tagged Erk2, p38α or Jnk1 plasmid was expressed in 293T cells. Immo-
bilized GST proteins for (i) WW domain of human ArhGAP9, (ii) N-terminal fragment of mouse ArhGAP9 (residues 1–350) or 
(iii) GST alone was incubated with the lysates. Bound Erk2, p38α or Jnk1 was detected by western blotting with α-Flag. (iv) 
Total cell lysates were immunoblotted with α-Flag. f. Erk2 interact with human but not mouse. Human or mouse ArhGAP9-Flag 
was expressed in 293T cells, individually or together with Erk2-HA. The lysates were immunoprecipitated with α-Flag. (i) 
Bound Erk2 was detected by western blotting with α-HA. (ii) Immunoprecipitated human or mouse ArhGAP9 was detected by 
α-Flag. Total cell lysates were immunoblotted with (iii) α-Flag or (iv) α-HA.
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The ArhGAP9 is a novel MAP kinase docking protein Figure 3
The ArhGAP9 is a novel MAP kinase docking protein. a. Alignment of the WW domains of ArhGAP9 and ArhGAP12. WW 
domains of human ArhGAP9 and ArhGAP12 were aligned using ClustalW, highlighted in yellow. The di-Arginine motif at the 
extreme C terminus of ArhGAP9 WW domain is highlighted in cyan. b. R246 and R247 in the WW domain of human ArhGAP9 
are required for binding to MAP kinases. Flag-tagged Erk2, p38α or Jnk1 was expressed in 293T cells and the lysates were incu-
bated with immobilized ArhGAP9-WW-GST, ArhGAP9-WW-(R246, 247A)-GST mutant, or GST alone as a control. Specifi-
cally MAP kinases were detected by western blotting with α-Flag. (ii) The expression levels of Erk2, p38α and Jnk1 were 
confirmed to be equivalent by immunoblotting of the total cell lysates with α-Flag. c. R246 and R247 are required for ArhGAP9 
WW domain binding to CD domain of MAP kinase in vitro. Flag-tagged ArhGAP9 (wild type or mutants R246A, R247A or R246, 
247A) was expressed in 293T cells and the lysates were incubated with the (i) Erk2-CD-GST or (ii) GST alone. Bound 
ArhGAP9 was detected by immunoblotting with α-Flag. (iii) Total cell lysates were immunoblotted with α-Flag. d. R246 and 
R247 are required for ArhGAP9 WW domain binding to MAP kinase in vivo. Flag-tagged Erk2 or p38α was expressed individually or 
together with full-length ArhGAP9 [wildtype or the R246, 247A mutant (RR)] in 293T cells, as indicated in the figure. The 
lysates were immunoprecipitated with α-Flag followed by western blotting of the immunocomplexes with (i) α-ArhGAP9 or 
(ii) α-Flag. Total cell lysates were immunoblotted with (iii) α-ArhGAP9 or (iv) α-Flag. e. K243, P244 and P245 within the WW 
domain of ArhGAP9 are also important for MAP kinase binding. Flag-tagged Erk2 were transiently expressed either individually or 
together with full-length ArhGAP9 [wildtype or K243A, P244A and P245A mutants] in 293T cells. The lysates were then sub-
jected to immunoprecipitation with α-Flag. The immunocomplexes were resolved by SDS-PAGE followed by western blotting 
with (i) α-ArhGAP9 or (ii) α-Flag. Total cell lysates were separated by SDS-PAGE and immunoblotted with (iii) α-ArhGAP9 
or (iv) α-Flag.
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---- - - -          +        
hArhGAP9-WW    RCPRSPPPGPACPLLQRLDAWEQHLDPNSGRCFYINSLTGCKSWKPPRRSRSETNPGSMEGTQT
hArhGAP12-WW-1 ISQSALPPLPGSPAIQINGEWETHKDSSGRCYYYNRGTQERTWKPPRWTRDASISKGDFQNPG-
hArhGAP12-WW-2 SEELDERGHTLYTSDYTNEKWLKHVDDQGRQYYYSADGSRSEWELPKYNASSQQQREIIKSRS-
   .  .       *  * *..** :* .       *: *: . .       ::.
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The Common Docking (CD) domain of MAP kinase mediated the binding to the WW domain of ArhGAP9 Figure 4
The Common Docking (CD) domain of MAP kinase mediated the binding to the WW domain of ArhGAP9. a. Flag-
tagged full-length ArhGAP9 (wild type or the R246,247A mutant, RR) was expressed 293T cells and the lysates were incubated 
with GST fusion of (i) the CD domain of Erk2 (Erk2-CD-GST, residues 300–358), (ii) a fragment of Erk2 deleted of the CD 
domain (Erk2-∆CD-GST, residues 1–300) or (iii) GST alone as a control. Bound ArhGAP9 was detected by western blotting 
with α-Flag. (iv) Total cell lysates were immunoblotted with α-Flag. b. Acidic residues in the CD domain of MAP kinases are impor-
tant for interaction with ArhGAP9. (i) Alignment of the Common Docking (CD) domains of Erk2, p38α and Jnk1, the acidic resi-
dues mutated to alanine are indicated in superscript. Flag-tagged Erk2 (wild type or D316A, D319A or E320A mutants) or 
p38α (wild type or D312A, D315A or E316A mutants) was expressed 293T cells. The lysates were incubated with (ii) 
ArhGAP9-WW-GST or (iii) GST alone. Bound Erk2 or p38α was detected by western blotting with α-Flag. (iv) Total cell 
lysates were immunoblotted with α-Flag. c. The activation loop of MAP kinase was not involved in binding with ArhGAP9. Flag-tagged 
Erk2 (wild type or T183, Y185A mutant) and p38α (wild type or T180, Y182A mutant) were expressed in 293T cells. The 
lysates were incubated with immobilized (i) ArhGAP9-WW-GST or (ii) GST alone. Bound Erk2 or p38α was detected by 
western blotting with α-Flag. (iii) Total cell lysates were immunoblotted with α-Flag. d. Far-UV CD spectra of WW of ArhGAP9 in 
complex with MAP kinase CD domain peptides. (i) The CD spectra of the WW domain of ArhGAP9 indicating that the protein 
folded properly and has mostly β-sheets and random coils. (ii-iv) CD spectra of ArhGAP9 WW domain in complex with Jnk1, 
p38α and Erk2 peptides, respectively. Conformational changes were observed for the case of ArhGAP9 WW domain in com-
plex with Erk2 and p38α peptides. As for Jnk1, little effect in the spectra profile was observed when compared with WW 
domain alone, indicating that no significant binding of the Jnk1 peptide had occurred. e. Structural alignment of the ArhGAP9-bind-
ing regions in the CD domains of Erk2, p38α and Jnk1. (i) A stereo view of structural alignment of Erk2 (red) with p38α (maroon) 
(ii) A stereo view of structural alignment of Erk2 with Jnk1. The residues are shown in stick model and the key mutated resi-
dues of Erk2 are marked.
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of ArhGAP9, point mutants of Erk2 and p38α as indicated
in Fig. 4b(ii) were generated and tested for their binding
to ArhGAP9. As shown in Fig. 4b(ii), the mutations
D316A in Erk2 and D312A, D315A, and E316A in p38α
caused a significant reduction in interaction with
ArhGAP9-WW domain. These results clearly indicated
that the acidic residues in the CD domains of Erk2 and
p38α were important for their interactions with ArhGAP9.
Other point mutations of Erk2 and p38α including amino
acid substitutions in the activation loop of the kinase
domain did not affect the binding (Fig. 4c). Further evi-
dence confirming that the WW domain of ArhGAP9 inter-
acted directly with the CD domains of Erk2 and p38 but
not Jnk1 was obtained by Far-UV circular dichroism spec-
troscopy (Fig. 4d). The WW domain is a small three-
stranded β-sheet stabilized by the stacking of several con-
served aromatic and proline residues [37-40]. Crystal and
solution structures of WW domains had shown that WW
domains undergo conformational changes upon binding
to its peptide ligands [19,20,41]. We applied Far-UV circu-
lar dichroism spectroscopy to investigate the conforma-
tional changes upon binding of Erk2, p38α or Jnk1
peptides corresponding to the common docking domains
to the WW domain of ArhGAP9. The peptides containing
14 amino acids in common docking domains of Erk2,
p38α and Jnk1 were synthesized [sequences shown in
Experimental procedures and in Fig. 4b(i)]. To analyze the
changes in the structure of WW domain upon binding of
corresponding peptides, the differences in the Far-UV cir-
cular dichroism spectrum of ArhGAP9 WW domain solu-
tions in the presence or absence of the peptides were
monitored. The changes in secondary structure contents
were analyzed using CDNN program, version 2.1 [42].
The analysis showed that the recombinant ArhGAP9 WW
domain folded properly and possessed mostly β-sheets
and random coils which are similar to the known WW
domains [Fig. 4d(i)]. In the presence of the Erk2 peptide
at equimolar concentration, ArhGAP9 WW domain
showed significant difference in the circular dichroism
spectra particularly from 190–205 nm [Fig. 4d(iv)]. In the
presence of p38α peptide, ArhGAP9 WW domain also
showed significant difference in the circular dichroism
spectra in the same region [Fig. 4d(iii)]. In contrast, the
addition of Jnk1 peptide did not alter the circular dichr-
oism spectra significantly although there were notable
changes at 220–235 nm [Fig. 4d(ii)]. These conforma-
tional changes monitored by Far-UV circular dichroism
were in agreement with the other known crystal and solu-
tion structures of WW proteins with their peptide targets.
This result further supported the conclusion from the in
vitro and in vivo experiments that both Erk2 and p38α
interacted with ArhGAP9-WW domain but Jnk1 did not.
However, the exact conformational changes and mecha-
nism of binding can be obtained only by solving the crys-
tal or solution structures of ArhGAP9-WW domain in
complex with its binding partners. The data described
above strongly indicated that the binding between
ArhGAP9 and the MAP kinases Erk and p38 is specific and
is mediated by the WW and CD domains of ArhGAP9 and
the MAP kinases, respectively.
To gain insights into the structural basis of specificity of
the WW domain of ArhGAP9 binding to Erk2, p38α and
Jnk1, we compared the three-dimensional structures of
CD domains of the three proteins. It could be seen from
the comparison that although the overall structures of
Erk2 (PDB id: 1ERK), p38α (PDB id: 1P38) and Jnk1
(PDB id: 1JNK) are very similar, the CD domain of p38α
shared greater homology than that of Jnk1 to Erk2. Fur-
thermore while Erk2 and p38α are significantly super-
imposable with RMSD of 0.68 Å [Fig. 4e(i)], Erk2 and
Jnk1 CD domains are relatively distinct with RMSD of
2.18 Å [Fig. 4e(ii)]. The high sequence and structural sim-
ilarity between Erk2 and p38α provided some insights
into the structural basis for the specificity on the WW
domain of ArhGAP9 for Erk2 and p38α but not Jnk1, as
observed in the binding studies in vitro and in vivo.
Coexpression of MAP kinase kinases (MAPKKs) reduced 
binding of MAP kinases (MAPKs) to WW domain of 
ArhGAP9
The CD domains of MAP kinases had been established as
the binding sites for their upstream activating kinases,
namely MEK1 and 2 for Erk1 and 2, and MKK3, 4 and 6
for p38α. [33,35,36,43]. Some other regulators, effectors
as well as MAP kinase substrates have also been estab-
lished to dock on the CD domains. These docking pro-
teins all contain positively charged residues that form the
docking (D) domain for binding with the CD domain of
MAP kinases [23,25-27]. From our data that the binding
of ArhGAP9 to Erk2 and p38α required a di-Arginine
motif in the WW domain and conserved acidic residues in
the CD domain, it was possible that the binding of D
domain containing proteins such as MEK2 and MKK6
may compete with the binding of ArhGAP9 to Erk2 and
p38α, respectively. We therefore compared the binding of
p38α to ArhGAP9-WW domain in the absence or presence
of overexpressed MKK6 [Fig. 5a(i)]. The amount of p38α
that precipitated with the WW domain ArhGAP9 was sig-
nificantly reduced in the presence of MKK6, indicating
that it was possible that the binding of MKK6 to p38α
could inhibit the binding of the WW domain ArhGAP9.
Consistent with the above in vitro data, the binding of full-
length ArhGAP9 to p38α in vivo was reduced in the pres-
ence of MKK6 (Fig. 5b). We had also observed that a
mutant of MKK6 with the basic residues in the D domain
responsible for binding to the CD domain of p38α
deleted failed to bind p38α and therefore to inhibit p38α
binding to the WW domain ArhGAP9 (data not shown).
Similarly, with the cotransfection of MEK2, the amount ofJournal of Molecular Signaling 2007, 2:1 http://www.jmolecularsignaling.com/content/2/1/1
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ArhGAP9 that co-immunoprecipitated with Erk2 was sig-
nificantly reduced (Fig. 5c). Taken together, these results
indicated that upstream activating kinases of p38α and
Erk2, namely MKK6 and MEK2, respectively were able to
disrupt the binding of the MAP kinases to the WW
domain of ArhGAP9, most likely due to their docking
onto the CD domains and competitively preventing the
binding of ArhGAP9.
Binding of ArhGAP9 inhibited Erk2 and p38α activation by 
upstream signals
Given that both ArhGAP9 and the MAP kinases possess
catalytic activities, we addressed the question of whether
their interaction would influence their activities. Furu-
kawa et al [7,17] as well as our data unpublished showed
that ArhGAP9 functioned as an active GTPase activating
protein (GAP) towards cdc42 and Rac1 but not RhoA. To
determine whether MAP kinase binding had any effect on
the RhoGAP activity of ArhGAP9, we compared the levels
of active cdc42 in the lysates of cells transfected with
ArhGAP9 in the presence or absence of Erk2 or p38α
using the Pak-binding domain (PBD) GST method (Fig.
5d). Through protein sequence alignment of the RhoGAP
domain of human ArhGAP9 and other known RhoGAPs
whose activities and structures have been determined, we
identified R578 in human ArhGAP9 as the 'Arginine fin-
ger' residue essential for GAP activity. We mutated R578
was to lysine and confirmed that ArhGAP9 (R578K) was
catalytically inactive by in vitro GAP assays (data not
shown). Using the GAP-inactive mutant of ArhGAP9
(R578K) as a negative control for the assay, there was
clearly no significant effect in the activity with or without
the presence of Erk2 or p38α.
We next investigated whether the binding of ArhGAP9 to
the Erk2 and p38α had an effect on the MAP kinase activ-
ities. 293T cells were transfected with p38α-Flag alone, or
p38α-Flag with EGFR to induce the activation of p38α, or
p38α with EGFR as well as ArhGAP9, either wild type or
the W242K, R246, 247A (WRR) triple mutant that was
defective in binding to Erk and p38, as indicated in Fig. 5e.
As shown by western blotting with α-phospho-p38 in Fig.
5e(v), p38α transfected alone showed a slight detectable
level of basal activation which increased significantly with
the coexpression of EGFR. With the expression of wild
type ArhGAP9, a reduction of p38α activation induced by
EGFR was observed, indicating that ArhGAP9 could sup-
press the activation of p38α downstream of EGFR. With
coexpression of the ArhGAP9 (WRR) mutant, there was a
slighter suppression of p38α activation by EGFR indicat-
ing that this mutant was able to partially restore p38α acti-
vation by EGFR inhibited by wild type ArhGAP9. This
result strongly suggested that the binding of ArhGAP9 to
MAP kinases prevented the activation of the latter by their
upstream kinases.
We further confirmed that this inhibitory effect was not
attributed to the RhoGAP activity but to the WW domain
of ArhGAP9. 293T cells were transfected with p38α-Flag
alone, or p38α-Flag with EGFR, or p38α with EGFR as
well as ArhGAP9, either wild type, the GAP-inactive
mutant (R578K) or the WW domain mutants (W219K or
W242K), as indicated in Fig. 5f. As shown in Fig. 5f(iv),
the suppressive effect of wild type ArhGAP9 on EGFR-
induced p38 activation was not affected by the R578K
mutation, but was partially reversed by the W219K or
W242K mutation.
Taken together, the above data demonstrated that (a) the
binding of ArhGAP9 to MAP kinases through its WW
domain caused the inhibition of MAP kinase activation by
upstream signals and (b) this interaction did not have a
significant effect on the RhoGAP activity of ArhGAP9. (c)
In addition, the inhibitory effect of ArhGAP9 on MAP
kinase activation was independent of its RhoGAP activity.
ArhGAP9 binding prevented MAP kinase-induced loss of 
actin stress fibres in fibroblasts
Rho GTPase and MAP kinase signaling have both been
implicated in the control of the actin cytoskeleton. Specif-
ically it was reported that activation of the MAP kinases
Erk1, 2 and 5 pathways caused disruption of the actin
cytoskeleton [44]. To investigate if the interaction of
ArhGAP9 and MAP kinases had an effect on the actin
cytoskeleton, ArhGAP9 (wild type or R246, 247A mutant)
and GFP-actin were heterologously expressed in Swiss 3T3
cells by microinjection of the respective cDNAs, followed
by live imaging of the actin structure. As shown in Fig. 6a,
in the presence of wild type ArhGAP9, the cells possessed
distinct bundles of actin stress fibres as in the control cells
where GFP-actin alone was expressed. However, in the
presence of the R246, 247A ArhGAP9 mutant, the stress
fibres dissolved and showed a diffuse cytosolic pattern of
actin distribution. These results supported the hypothesis
that binding of wild type ArhGAP9 to MAP kinases
sequestered them in the inactive forms, preventing the
activation of the MAP kinases and therefore allowing the
formation and maintenance of actin stress fibres in
fibroblasts. Conversely, the R246, 247A mutant being
unable to bind the MAP kinases, would potentially allow
activation of the MAP kinases to result in the disassembly
of the actin stress fibres.
Discussion
ArhGAP9 is a recently identified RhoGAP which contains
four functional domains including SH3, WW, PH and
RhoGAP. Interestingly, the rodent orthologs do not con-
tain the WW domain despite sharing more than 60%
identity with the canine, bovine and primate proteins. We
focused on studying the role(s) of the WW domain in
human ArhGAP9 and demonstrated that it possesses aJournal of Molecular Signaling 2007, 2:1 http://www.jmolecularsignaling.com/content/2/1/1
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ArhGAP competes with MAP kinase kinases (MAPKKs) to suppress MAP kinase activation Figure 5
ArhGAP competes with MAP kinase kinases (MAPKKs) to suppress MAP kinase activation. a. Coexpression of MKK6 
dimished the binding of p38α to the WW domain of ArhGAP9. p38α-Flag was transfected alone or together with HA-tagged acti-
vated mutant of MKK6 in 293T cells and the lysates were incubated with (i) ArhGAP9-WW-GST or (ii) GST alone as a con-
trol. Bound p38α was detected by western blotting with α-Flag. (iii, iv) Total cell lysates were immunoblotted with α-Flag or α-
HA, respectively. b. Overexpression of MKK6 diminished the binding between ArhGAP9 and p38α. Flag-tagged p38α, HA-tagged 
MKK6 and ArhGAP9 were expressed in 293T cells as indicated in the figure. The immunocomplex of p38α was analyzed by 
western blotting with (i) α-ArhGAP9 and (ii) α-Flag. (iii-v) Total lysates were immunoblotted with α-ArhAGAP9, α-Flag and α-
HA, respectively. c. Reduction of ArhGAP9 binding to Erk2 by MEKoverexpression in vivo. Flag-tagged Erk2, HA-tagged MEK2 and 
ArhGAP9 were transiently transfected in 293T cells as indicated in the figure. Immunoprecipitation was carried out with α-
ArhGAP9, followed by western blotting with (i) α-ArhGAP9 α-Flag and (ii) α-HA. Western blotting of the total lysates with 
(iii) α-phospho-Erk showed that Erk2 was activated when coexpressed with MEK2. Western blotting of the total lysates with 
(iv) α-ArhAGP9, (v) α-Flag and (vi) α-HA showed the expression of ArhGAP9, Erk2 and MEK2 in the total cell lysates. d. MAP 
kinase binding has no significant effect on ArhGAP9 RhoGAP activity. ArhGAP9 (wild type or the GAP-inactive mutant, R578K) was 
transfected with myc-tagged Cdc42, as well as Flag-tagged Erk2 or p38α in 293T cells, as indicated in the figure. (i) The lysates 
were incubated with immobilized PBD-GST followed by detection of the relative amounts of active cdc42 precipitated by west-
ern blotting with α-myc. (ii) GST alone was used as a control. (iii-v) Total cell lysates were immunoblotted with α-ArhGAP, α-
Flag or α-myc, rspectively. e. ArhGAP9 binding suppresses MAP kinase activation by EGFR. ArhGAP9 [wild type or the triple mutant 
W242K, R246A, R247A (WRR)] was expressed in 293T cells alone or with EGFR and Flag-tagged p38α, as indicated in the fig-
ure. (i-v) Total cell lysates were immunoblotted with antibodies to EGFR, phosphotyrosine, ArhGAP9, Flag epitope or phos-
pho-p38α. f. RhoGAP activity of ArhGAP9 is not required for its suppression of MAP kinase activation. Wild type ArhGAP9 or the 
mutants R578K (GAP-inactive), WW-1 (W219K) and WW-2 (W242K) were cotransfected with EGFR and p38α in 293T cells. 
(i-iv) Total cell lysates were immunoblotted with antibodies to phosphotyrosine, ArhGAP9, Flag epitope or phospho-p38α.
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a. Expression of ArhGAP9 R246, 247A mutant disrupts stress fibres in Swiss 3T3 fibroblasts Figure 6
a. Expression of ArhGAP9 R246, 247A mutant disrupts stress fibres in Swiss 3T3 fibroblasts. Swiss 3T3 cells were microinjected with 
full-length ArhGAP9 (wild type or the R246, 247A (RR) mutant) together with GFP-actin. The cells were imaged for GFP fluo-
rescence. b. Proposed mechanism of negative regulation of MAP kinase by ArhGAP9. ArhGAP9 contains a WW domain which pos-
sesses a basic di-Arginine motif while MAP kinase (MAPK) contains a Common Docking (CD) domain that contains conserved 
acidic residues. In quiescent state, ArhGAP9 interacts with MAPK through electrostatic interaction between the complemen-
tary basic and acidic residues in the WW and CD domains, respectively thus blocking the access of MAPK by other docking 
proteins and negatively regulating MAPK activation. In the induced state, the presumable increase in local concentration of 
active upstream MAPK kinase (MAPKK) displaces ArhGAP9 by docking onto CD domain of MAPK, causing the diminished 
binding of ArhGAP9 to MAPK. The interaction between MAPK and MAPKK results in the phosphorylation of MAPK in the 
kinase activation loop to activate the latter.
a 
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n=10 (2 expts) 
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b 
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unique ligand specificity. Using proteomics and mass
spectrometry we found that the WW domain of the
human ArhGAP9 associated specifically with the MAP
kinase, Erk2. The WW domain of ArhGAP9 also bound to
another member of the MAP kinase family, p38α, albeit
with an apparently less affinity but not to Jnk1. The Erk2
and p38α proteins do not contain any PPDY, PPLP,
PPPPP, PPXPPXR, PPRXXP, PR motifs or (pT/pS)-P deter-
mined for WW domain binding, indicating that the WW
domain of ArhGAP9 had a novel ligand specificity distinct
from the four groups currently established. We further
showed that the binding of the WW domain of ArhGAP9
with Erk2 or p38α was mediated through complementa-
rily charged residues between the C-terminal end of the
WW domain of ArhGAP9 and the conserved Common
Docking (CD) domain in Erk2 or p38α and proposed that
ArhGAP9 is a novel Erk2 and p38α docking protein. The
binding between the WW domain of human ArhGAP9
and the MAP kinases is most likely not solely mediated by
the electrostatic interactions between the di-Arginine
motif in the WW domain of ArhGAP9 and the acidic resi-
dues in the CD domain of the MAP kinases. These interac-
tions may however be important in providing electrostatic
steering forces to control the rate of association or specif-
icity of binding. The three-dimensional structure of Erk2
shows that the CD domain was located on the opposite
surface of Erk2 from the activation loop, supporting our
data that the activation loop region was not involved in
binding to the WW domain of ArhGAP9. In this study, we
have identified that a di-Arginine motif (R246 and R247)
in the C-terminal region of the WW domain of ArhGAP9
was important for the binding to MAP kinases as the
mutation of these basic residues either individually or
together abolished the binding of full-length ArhGAP9 or
the WW domain alone to Erk2 or p38α. We have also
mapped the acidic residues in the CD domains of Erk2
and 38α required for binding to the WW domain of
ArhGAP9. The residues D316 in Erk2 and D312, D315,
and E316 in p38α have been found to be important for
binding to ArhGAP9. While it is clear that the di-Arginine
motif in the C-terminal region of the WW domain as well
as the two signature tryptophan residues were important
for binding to Erk2 and p38α, the overall structural mech-
anism of MAP kinases binding to the WW domain of
ArhGAP9 and the other residues on the WW domain and
the MAP kinases that might also contribute to the binding
specificity and affinity remains to be determined. The
determination of the three-dimensional structure of the
ArhGAP9 WW domain in a complex with Erk2 or p38α
will provide further evidence on the contribution of other
regions of the WW domain and MAP kinases in the inter-
action.
The binding of human ArhGAP9 and the MAP kinases
Erk2 and p38α represents another example of the recently
discovered cross-talk mechanism between the Rho
GTPase and MAP kinase signaling pathways. There are 2
recent reports of examples of RhoGAPs interacting with
Erk, namely IQGAP1 and CdGAP. In the case of IQGAP1,
Erk2 binds to the WW domain of IQGAP1 although the
specific residues involved had not been elucidated. The
overexpression or reduction of IQGAP1 expression by
siRNA both caused the activation of Erk2 by EGF or IGF-1
in MCF-7 cells to be reduced, probably due to an optimal
level of intracellular IQGAP1 being necessary for maximal
level of activation of Erk by EGF or IGF-1 [45]. The WW
domain of IQGAP1 does not contain basic residues anal-
ogous to R246 and R247 in ArhGAP9 and we had found
that it bound Erk2 with a much lower affinity that
ArhGAP9 (data not shown). In the case of CdGAP, Erk1
binds to the RhoGAP through a putative DEF (Docking
for Erk FXFP), resulting in phosphorylation of the
RhoGAP by the MAP kinase and inhibition of its RhoGAP
activity [46]. CdGAP does not contain a WW domain and
is therefore expected to associate with Erk through a differ-
ent docking mechanism.
The RhoGAP activity of ArhGAP9 was not significantly
altered as a result of the interaction with MAP kinases but
rather, the activation of the MAP kinases was suppressed
by the interaction. The binding of Erk2 or p38α to
ArhGAP9 was significantly reduced in the presence of
MAP kinase docking proteins such as upstream activating
kinases, namely MEK2 for Erk2 or MKK6 for p38α. We
hypothesized that in the quiescent state, ArhGAP9 may
bind to Erk2 or p38α in the cell through its WW domain
docking on the CD domain of the MAP kinases. When
upstream signals were elicited to activate the MAP kinases,
the binding of ArhGAP9 was diminished probably due to
competitive displacement by other docking proteins,
namely the MAP kinase kinases, MEK for Erk and MKK3,
4 or 6 for p38. The subcellular localization and concentra-
tions of the docking proteins are most likely key determin-
ing factors of the docking interactions with MAP kinases.
We have proposed a model for the negative regulation of
MAP kinase signaling by ArhGAP9 as illustrated in Fig. 6b.
Consistent with this hypothesis, our data showed that
while wild type ArhGAP9 significantly suppressed Erk2 or
p38α activity induced by EGFR, the mutants of ArhGAP9
that was defective in binding to the MAP kinases resulted
in only marginal suppression of EGFR-induced MAP
kinase activation.
Both the Erk and p38 MAP kinases play pivotal signaling
roles in development and cellular processes, including
cytoskeletal changes that underlie increased cell motility
and decreased cell adhesion in transformation and metas-
tasis. In almost all types of cancers, the Erk MAP kinase is
constitutively active, conferring increased proliferation
and resistance to apoptotic stimuli, including chemicalJournal of Molecular Signaling 2007, 2:1 http://www.jmolecularsignaling.com/content/2/1/1
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cytotoxic drugs. The Erk MAP kinase is therefore a highly
relevant target for therapeutic intervention in cancer.
Extensive published literature has demonstrated that the
Ras/Raf/Erk pathway downstream of ras or src oncogenes
was required for disruption of actin stress fibres and focal
adhesions in different transformed cell lines, indicating
the importance of Erk 1 and 2 activity in actin cytoskele-
ton remodeling [44,47-49]. Activation of Erk in trans-
formed cells has been shown to cause the down-
regulation of Rho-kinase expression [49] and activation of
LIM kinase [50,51]. Rho-kinase phosphorylates myosin
light chains and negatively regulates myosin phosphatase,
which result in increased acto-myosin-based contractility
[52,53] which contribute to the formation of stress fibres
and focal contacts. LIM kinase phosphorylates cofilin to
result in the inhibition of its actin-depolymerization activ-
ity thus contributing to actin fibre stabilization [50,51].
Consistent with these reported roles of Erk activity in the
control of the actin cytokeleton, our results showed that
expression of wild type ArhGAP9 preserved the stress
fibres in fibroblasts. In contrast, expression of the R246,
247A mutant defective in binding to Erk caused dramatic
disassembly of actin stress fibres, with the unpolymerized
actin distributed to the cytosol.
Our data collectively demonstrated that ArhGAP9 is a
novel docking protein of the MAP kinases Erk and p38,
but not Jnk. Through a series of biochemical, biophysical
and cell-based experiments, we have provided evidence
that the activation of the MAP kinases by upstream acti-
vating kinases was suppressed by ArhGAP9 binding both
in vitro and in vivo. This provides a basis for a previously
unexplored molecular mechanism to modulate MAP
kinase activity and could be explored further for develop-
ment of novel inhibitors of MAP kinase signaling by dis-
ruption of MAP kinase binding to docking proteins at the
CD domain. This strategy should allow higher selectivity
in targeting MAP kinases compared to the more general
ATP-binding interference approach. Indeed, using the
computer-aided drug design (CADD) approach, novel
compounds that disrupt the interactions between Erk and
their docking proteins through the CD and D domains
have been identified and shown to be effective in blocking
Erk activation in cells [34,54-56].
Materials and methods
Antibodies
α-Flag (M2) and α-phospho-p38 were from Sigma, α-
phospho-Erk was from Cell Signaling Technology, α-HA
(12CA5) was from Boerhinger, α-ArhGAP9 was generated
by standard immunization procedure with full-length
human ArhGAP9-GST as the immunogen. α-phosphoty-
rosine conjugated to horse radish peroxidase (PY20-HRP)
was from Transduction Laboratories, α-EGFR was from
Santa Cruz Biotechnology.
Cell lines
293T cells were cultured in Dulbecco's minimal essential
medium (DMEM) containing 4.5 g/l D-glucose, 10% (v/
v) fetal bovine serum (HyClone), 10 mM L-glutamine,
and 100 µg each of penicillin and streptomycin/ml from
Sigma. Swiss 3T3 were cultured in DMEM containing 4.5
g/l D-glucose, 10% (v/v) Cosmic calf serum (HyClone),
10 mM L-glutamine, and 100 µg each of penicillin and
streptomycin/ml.
Plasmids
Human ArhGAP9 (wild type and mutants) and EGFR cod-
ing cDNAs were cloned into the mammalian expression
vector pRK5. Erk2, p38, Jnk1 cDNAs were cloned in
pxJ40-Flag vector with an N-terminal Flag tag. HA-tagged
activated MEK2(S222D, S226D) was cloned in pUSEamp
vector. Activated MKK6(S207E, T211E) was cloned in
pxJ40-HA vector. Plasmid encoding Pak-binding domain
(PBD)-GST was obtained from Dr. E Manser (CMM, A-
STAR, Singapore). Cdc42-myc was cloned in pcDNA3. For
transient expression in mammalian cells, Lipofectamine
(Gibco BRL) was used for transfection, following the pro-
tocol recommended by the manufacturer. Point muta-
tions were introduced with the Quikchange site-directed
mutagenesis kit (Stratagene) and the mutations were con-
firmed by DNA sequencing.
Protein expression and purification
For expression of glutathione S-transferase (GST) fusion
proteins, cDNA sequences were cloned into the pGEX4T1
vector (Pharmacia). The GST fusion proteins were
expressed in E. coli BL21 (DE3) cells and purified using
glutathione sepharose 4B column chromatography
(Amersham). For Far-UV CD spectroscopy, the GST tag
was cleaved with the thrombin protease by overnight on-
column digestion at 4°C. The resulting protein prepara-
tion was then further purified by using ion-exchange
Mono Q Sepharose column (Amersham) which had been
pre-equilibrated with buffer A (20 mM Tris-HCl pH 7.5).
The protein was then eluted from the column with a linear
gradient to buffer B (20 mM Tris-HCl pH 7.5, 1 M NaCl).
The protein was further purified using Superdex-75 gel fil-
tration column chromatography in Biologic Duoflow
FPLC system.
Proteomics and mass spectrometry analysis
Protein complexes of the WW domain of human
ArhGAP9 isolated from rat brain lysate were eluted and
resolved by 10% SDS-PAGE, followed by detection of
bound proteins by staining with Colloidal Coomassie
Blue (Pierce). Specific bands were excised and subjected to
in-gel reduction, S-alkylation and trypsin hydrolysis. Liq-
uid-chromatography tandem mass spectrometry (LC-MS/
MS) analysis of the peptides was performed on a Finnigan
LCQ Deca ion trap mass spectrometer (Thermo Finnigan)Journal of Molecular Signaling 2007, 2:1 http://www.jmolecularsignaling.com/content/2/1/1
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fitted with a Nanospray source (MDS Proteomics). Chro-
matographic separation was conducted using a Famos
autosampler and an Ultimate gradient system (LC Pack-
ings) over Zorbax SB-C18 reverse phase resin (Agilent)
packed into 75 µm PicoFrit columns (New Objective).
Protein identifications were made using the search
engines Mascot (Matrix Sciences) and Sonar (ProteoMet-
rics).
In vitro binding assays
Lysates for binding assays and immuno-precipitation
were prepared by lysis of cells in the cell lysis buffer [20
mM HEPES (pH 7.5), 137 mM NaCl, 1% Triton X-100,
10% glycerol, 1.5 mM MgCl2, 1 mM EGTA, 0.1 mM
Na3VO4 and Complete Protease inhibitors (Boehringer)],
followed by centrifugation 13,000 g for 15 min at 4°C
and collecting the supernatant. For in vitro pulldown
assays, GST fusion proteins immobilized on glutathione
beads were incubated with the lysates for 1 hour at 4°C
with rotation, followed by washing of the beads with spe-
cifically bound proteins with cell lysis buffer for 5 times,
each time for 5 min with rotation at 4°C. The protein
complexes were then eluted with Laemmli Buffer and
resolved by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), followed by blotting onto
PVDF membranes and detection with specific antibodies.
For immuno-precipitation, antibodies were added to the
lysates and incubated for 1 hour at 4°C with rotation, fol-
lowed by addition of Protein A PLUS G beads (Calbio-
chem) to capture the immuno-complexes. The immuno-
complexes were washed and then eluted with Laemmli
Buffer and resolved by SDS-PAGE, followed by western
blotting with specific antibodies.
Peptides and Far UV Circular Dichroism (CD) spectroscopy
Peptides for Erk2: LEQYYDPSDEPIAE, p38α: FAQYHDP-
DEPVAD and Jnk1: INVWYDPSEAEAPP were custom syn-
thesized by NeoSystems (Strasbourg, France). CD
experiments were performed with a Jasco J-715 spectropo-
larimeter equipped with a Peltier cell holder and a PTC-
348WI temperature controller. Far-UV CD spectra were
measured in a 1-mm rectangular quartz cell. The buffer
used was 20 mM Tris-HCl (pH 7.5), 500 mM NaCl and 1
mM DTT. Protein concentration of approximately 0.5 mg/
ml determined by the Bradford assay method was used for
wavelength scans. Wavelength scans were made at a scan
rate of 10 nm/min and the average value of 3 scans of the
same solution were obtained. Data were collected at 25°C
over a wavelength range 190–260 nm with a bandwidth
of 1 nm. To determine the conformational changes in
WW domain upon peptide binding, the ellipticity of the
corresponding peptides at equimolar concentration with
the solvent were subtracted from the ellipticity of the WW
domain-peptide complex and similarly the solvent spec-
trum were subtracted from the spectrum of WW domain
before analysis. The far UV CD spectra were analyzed by
using the secondary structure analysis program CDNN,
version 2.1 [42].
Microinjection and live cell imaging
Swiss 3T3 fibroblasts were plated at 5 × 104 per glass bot-
tom dish and grown overnight at 37°C in DMEM with
10% Cosmic calf serum. DNA was injected at 0.5 µg/ml
into the nuclei using a custom setup microinjector and
Olympus microscope (Olympus IMT-2) and the cells were
returned to incubation at 37°C overnight to allow for pro-
tein expression. For DIC and fluorescence time-lapse anal-
ysis, cells were incubated on a heated stage at 37°C and
imaged with a monochromator on a Zeiss Axiovert 200 M
microscope enclosed in an incubator with CoolSNAP
CCD camera.
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